Leerink Partnrs Upgrades Replimune Group (NASDAQ:REPL) to "Strong-Buy"

Key Points

• Leerink Partners has upgraded Replimune Group from a "hold" to a "strong-buy" rating, increasing their price target from $3.00 to $13.00.
• Other analysts have expressed mixed views, with BMO Capital Markets downgrading the stock from "outperform" to "underperform," lowering its price target significantly from $27.00 to $2.00.
• Replimune Group reported a Q2 loss of ($0.95) EPS, which missed analyst expectations, and is anticipated to post a total EPS of ($2.97) for the current fiscal year.

Replimune Group (NASDAQ:REPL - Get Free Report) was upgraded by equities researchers at Leerink Partnrs from a "hold" rating to a "strong-buy" rating in a research note issued on Monday,Zacks.com reports.

A number of other equities analysts have also commented on the company. BMO Capital Markets lowered Replimune Group from an "outperform" rating to an "underperform" rating and lowered their price objective for the stock from $27.00 to $2.00 in a research note on Wednesday, July 23rd. Piper Sandler upgraded Replimune Group from a "neutral" rating to an "overweight" rating and set a $13.00 price target on the stock in a research note on Monday. Barclays lowered Replimune Group from an "overweight" rating to an "equal weight" rating and decreased their price target for the company from $17.00 to $3.00 in a research note on Wednesday, July 23rd. Leerink Partners upgraded Replimune Group from a "market perform" rating to an "outperform" rating and lifted their price target for the company from $3.00 to $13.00 in a research note on Monday. Finally, Wedbush upgraded Replimune Group from a "neutral" rating to an "outperform" rating and lifted their price target for the company from $4.00 to $18.00 in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $11.00.

Replimune Group Price Performance

Replimune Group stock opened at $8.94 on Monday. The stock's fifty day moving average price is $5.11 and its two-hundred day moving average price is $7.28. Replimune Group has a one year low of $2.68 and a one year high of $17.00. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.94 and a quick ratio of 6.94. The firm has a market cap of $697.86 million, a PE ratio of -2.76 and a beta of 0.42.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). As a group, research analysts expect that Replimune Group will post -2.97 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Emily Luisa Hill sold 9,154 shares of the business's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $5.37, for a total transaction of $49,156.98. Following the sale, the chief financial officer owned 134,368 shares in the company, valued at $721,556.16. The trade was a 6.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 5.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of REPL. US Bancorp DE lifted its holdings in Replimune Group by 582.6% during the 1st quarter. US Bancorp DE now owns 4,594 shares of the company's stock worth $45,000 after buying an additional 3,921 shares during the period. BNP Paribas Financial Markets lifted its holdings in Replimune Group by 37.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company's stock worth $64,000 after buying an additional 1,879 shares during the period. Raymond James Financial Inc. acquired a new position in Replimune Group during the 2nd quarter worth about $69,000. Griffin Asset Management Inc. acquired a new position in Replimune Group during the 3rd quarter worth about $82,000. Finally, Tower Research Capital LLC TRC lifted its holdings in Replimune Group by 2,020.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,692 shares of the company's stock worth $90,000 after buying an additional 9,235 shares during the period. 92.53% of the stock is owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.